In addition to our own research and development activities, Crucell has formed strategic agreements with several leading companies. Through these agreements, our technologies are playing a vital role in the development of a number of vaccine and antibody products.

DSM Biologics

In December 2002, Crucell formed an alliance with DSM Biologics to license Crucell’s PER.C6^® human cell line as a production platform for monoclonal antibodies and recombinant proteins. The combination of the PER.C6^® human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. Furthering this commitment to the PER.C6^® cell line, Crucell and DSM have established a joint PER.C6^® R&D Center in Cambridge, Massachusetts, named PERCIVIA. The innovations resulting from this partnership will be available to licensees to further enhance their development capabilities.

 

• www.dsmbiologics.com
• www.percivia.com

Novartis

In March 2006, the Korea Food and Drug Administration (KFDA) awarded licensure to Quinvaxem^®, a fully liquid pentavalent pediatric vaccine. The vaccine is produced by Crucell in Korea and was co-developed with Chiron Corporation (now Novartis), which provides four of the five vaccine components as bulk.

 

• www.novartis.com

sanofi pasteur

In December 2007, Crucell and sanofi pasteur signed an exclusive collaboration and commercialization agreement for Crucell's rabies monoclonal antibodies, next-generation rabies biologicals, to be used with rabies vaccine for post-exposure prophylaxis against this fatal disease.

 

• www.sanofipasteur.com

Wyeth

In July 2007 Crucell entered into a co-exclusive license agreement with Wyeth Pharmaceuticals, a division of Wyeth, for the use of our PER.C6^® and Advac^® technology.

 

In March 2008 both companies entered into an exclusive vaccine development agreement. Crucell is responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities takes place in Crucell's dedicated vaccine manufacturing facilities in Bern, Switzerland.

  

• www.wyeth.com